CTOs on the Move

Bionano Genomics

www.bionanogenomics.com

 
At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what`s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Kai Pharmaceuticals

Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeServe Blood Center

LifeServe Blood Center is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Health Media

New York-based Precision Health Media (formerly Good Health Media) delivers specific health condition audiences to pharma and consumer brands.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.